Silex Systems (ASX:SLX) shares suffered a sharp sell-off on Monday, falling around 13.3% and ranking among the worst performers in the ASX 200. The drop came after SLX closed at A$5.96 on Friday following a strong run over the previous week. Importantly, Silex did not release a fresh company announcement on Monday that directly explained the fall. Instead, the move appears to reflect profit-taking, weakness across uranium-related shares and renewed attention on the company’s continuing losses as it works towards commercialising its enrichment technology.
Why Did Silex Systems Shares Fall 13%?
One reason may simply be how quickly SLX had risen before Monday.
Silex shares closed at A$5.11 on August 21 and climbed to A$5.96 by August 28. That represents a gain of roughly 17% in just five trading sessions. Monday’s decline therefore came after investors had already pushed the shares sharply higher.
There was also broader weakness in uranium-related stocks. ABC’s market coverage showed Silex leading the ASX 200’s bottom movers during Monday’s session and noted that other uranium-linked companies were also among the day’s weaker performers.
That combination may have encouraged investors to lock in recent gains.
What Did Silex Report in FY26?
Silex released its FY26 results on August 27, and the numbers showed both progress and an important risk.
Revenue from ordinary activities increased 77% to A$21.6 million, compared with A$12.2 million a year earlier. However, Silex remained loss-making, reporting a net loss after tax of A$38.62 million. That was an improvement from the A$42.56 million loss reported in FY25.
The company’s balance sheet remains much stronger.
Silex ended FY26 with approximately A$180.7 million in cash and term deposits following capital raisings during the year. Management also reported no corporate debt.
That gives Silex substantial funding capacity, but the company is still spending heavily while its major technologies move towards commercialisation.
Why Is the Uranium Story Still Important?
The long-term Silex investment case remains closely linked to Global Laser Enrichment, or GLE.
Silex owns 51% of GLE, while uranium producer Cameco owns the remaining 49%. GLE is the exclusive licensee of Silex’s laser-based uranium enrichment technology.
The technology reached Technology Readiness Level 6 in October 2025, an important development milestone for the commercialisation program.
One of the biggest opportunities is the proposed Paducah project in Kentucky. Silex says the project could potentially produce the equivalent of up to 5 million pounds of uranium oxide annually for as long as 30 years. It could later also support production of enriched uranium for conventional nuclear reactors and advanced reactors.
However, these opportunities are not guaranteed. Commercialisation remains dependent on factors including feasibility work, licensing, market conditions, funding and government support.
What Should SLX Investors Watch Next?
The biggest issue for investors is whether Silex can turn its technology progress into commercial revenue and eventually sustainable profits.
Progress at GLE and the Paducah project will therefore remain critical. Investors should also watch the company’s Quantum Silicon project, where construction of its Sydney production plant has been completed and commissioning is underway.
Short-term movements in uranium stocks could also continue to create volatility in SLX shares.
Conclusion
Silex Systems’ 13% fall does not appear to have been caused by one new piece of bad news.
Instead, Monday’s sell-off followed a strong run in SLX shares and came during broader weakness in uranium-related stocks. FY26 also reminded investors that despite growing revenue and a strong cash position, Silex remains loss-making as it invests heavily in commercialisation.
For SLX investors, the long-term story now depends on whether progress in uranium enrichment and other applications can eventually turn Silex’s promising technology into meaningful commercial earnings.
